Genprex stockholders approve reverse split (1:10-1:50), 6.5M new shares for equity plan

Genprex, Inc.

• Approved Amended & Restated 2018 Equity Plan, adding 6,500,000 shares and extending term to June 30, 2035.
• Authorized reverse stock split at ratio between 1:10 and 1:50, to be implemented at Board's discretion before Dec 31, 2026.
• Approved issuance of >20% of common stock to Lincoln Park Capital Fund under purchase agreement.
• Stockholders ratified WithumSmith+Brown as independent auditor for FY2025 with 14.2M votes for vs 1.5M against.
• Director William R. Wilson Jr. reelected with 5.6M votes for; broker non-votes of 9.6M on multiple proposals.